Granza Bio

Granza Bio, previously named Zyme Therapeutics, operates out of San Francisco, CA, and is a participant in the Y Combinator W24 batch. The company, employing a team of two, focuses on the healthcare sector, specifically within therapeutics. Granza Bio is pioneering in the development of cancer therapeutics by engineering attack particles that exclusively target cancer cells without affecting healthy cells. These particles have demonstrated effectiveness against various cancers including glioblastoma, ovarian, lung, and skin cancers. Additionally, their platform holds potential for addressing a broad spectrum of diseases beyond cancer, such as autoimmune diseases and infections. Granza Bio serves a wide range of regions including the United States of America, America/Canada, and also offers remote and partly remote services.